Literature DB >> 9111313

A-myb is expressed in bovine vascular smooth muscle cells during the late G1-to-S phase transition and cooperates with c-myc to mediate progression to S phase.

D J Marhamati1, R E Bellas, M Arsura, K E Kypreos, G E Sonenshein.   

Abstract

The Myb family of transcription factors is defined by homology within the DNA binding domain and includes c-Myb, A-Myb, and B-Myb. The protein products of the myb genes all bind the Myb-binding site (MBS) [YG(A/G)C(A/C/G)GTT(G/A)]. A-myb has been found to display a limited pattern of expression. Here we report that bovine aortic smooth muscle cells (SMCs) express A-myb. Sequence analysis of isolated bovine A-myb cDNA clones spanning the entire coding region indicated extensive homology with the human gene, including the putative transactivation domain. Expression of A-myb was cell cycle dependent; levels of A-myb RNA increased in the late G1-to-S phase transition following serum stimulation of serum-deprived quiescent SMC cultures and peaked in S phase. Nuclear run-on analysis revealed that an increased rate of transcription can account for most of the increase in A-myb RNA levels. Treatment of SMC cultures with 5,6-dichlorobenzimidazole riboside, a selective inhibitor of RNA polymerase II, indicated an approximate 4-h half-life for A-myb mRNA during the S phase of the cell cycle. Expression of A-myb by SMCs was stimulated by basic fibroblast growth factor, in a cell density-dependent fashion. Cotransfection of a human A-myb expression vector activated a multimerized MBS element-driven reporter construct approximately 30-fold in SMCs. The activity of c-myb and c-myc promoters, which both contain multiple MBS elements, were similarly transactivated, approximately 30- and 50-fold, respectively, upon cotransfection with human A-myb. Lastly, A-myb RNA levels could be increased by a combination of phorbol ester plus insulin-like growth factor 1. To test the role of myb family members in progression through the cell cycle, we comicroinjected c-myc and myb expression vectors into serum-deprived quiescent SMCs. The combination of c-myc and either A-myb or c-myb but not B-myb synergistically led to entry into S phase, whereas microinjection of any vector alone had little effect on S phase entry. Thus, these results suggest that A-myb is a potent transactivator in bovine SMCs and that its expression induces progression into S phase of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111313      PMCID: PMC232093          DOI: 10.1128/MCB.17.5.2448

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  70 in total

1.  The v-myb oncogene product binds to and activates the promyelocyte-specific mim-1 gene.

Authors:  S A Ness; A Marknell; T Graf
Journal:  Cell       Date:  1989-12-22       Impact factor: 41.582

Review 2.  G1 events and regulation of cell proliferation.

Authors:  A B Pardee
Journal:  Science       Date:  1989-11-03       Impact factor: 47.728

3.  Myb and Ets proteins cooperate in transcriptional activation of the mim-1 promoter.

Authors:  H Dudek; R V Tantravahi; V N Rao; E S Reddy; E P Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

4.  The cellular oncogene c-myb can interact synergistically with the Epstein-Barr virus BZLF1 transactivator in lymphoid cells.

Authors:  S C Kenney; E Holley-Guthrie; E B Quinlivan; D Gutsch; Q Zhang; T Bender; J F Giot; A Sergeant
Journal:  Mol Cell Biol       Date:  1992-01       Impact factor: 4.272

5.  trans activation of gene expression by v-myb.

Authors:  C E Ibanez; J S Lipsick
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

6.  Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene.

Authors:  D McClinton; J Stafford; L Brents; T P Bender; W M Kuehl
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

7.  Delineation of three functional domains of the transcriptional activator encoded by the c-myb protooncogene.

Authors:  H Sakura; C Kanei-Ishii; T Nagase; H Nakagoshi; T J Gonda; S Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

8.  Positive autoregulation of c-myb expression via Myb binding sites in the 5' flanking region of the human c-myb gene.

Authors:  N C Nicolaides; R Gualdi; C Casadevall; L Manzella; B Calabretta
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

9.  Concerted modulation of alpha 1(XI) and alpha 2(V) collagen mRNAs in bovine vascular smooth muscle cells.

Authors:  K E Brown; R Lawrence; G E Sonenshein
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

10.  Expression of c-myb in embryonal carcinoma cells and embryonal stem cells.

Authors:  P J Dyson; F Poirier; R J Watson
Journal:  Differentiation       Date:  1989-10       Impact factor: 3.880

View more
  5 in total

Review 1.  Conservation and diversification of three-repeat Myb transcription factors in plants.

Authors:  Masaki Ito
Journal:  J Plant Res       Date:  2005-02-10       Impact factor: 2.629

2.  Glucocorticoids regulate gene expression and repress cellular proliferation in human uterine leiomyoma cells.

Authors:  Shannon Whirledge; Darlene Dixon; John A Cidlowski
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

3.  Myb controls G(2)/M progression by inducing cyclin B expression in the Drosophila eye imaginal disc.

Authors:  Masahiro Okada; Hiroshi Akimaru; De-Xing Hou; Tomomi Takahashi; Shunsuke Ishii
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

4.  RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members.

Authors:  H Y Jiang; Constantinos Petrovas; Gail E Sonenshein
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 5.  Situational awareness: regulation of the myb transcription factor in differentiation, the cell cycle and oncogenesis.

Authors:  Olivia L George; Scott A Ness
Journal:  Cancers (Basel)       Date:  2014-10-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.